Molecular genetics of B-precursor acute lymphoblastic leukemia
Open accessThe DOI matches its Crossref record; 126 of the 127 references it cites were found in a registry or an index.
Abstract
B-precursor acute lymphoblastic leukemia (B-ALL) is the most common childhood tumor and the leading cause of cancer-related death in children and young adults. The majority of B-ALL cases are aneuploid or harbor recurring structural chromosomal rearrangements that are important initiating events in leukemogenesis but are insufficient to explain the biology and heterogeneity of disease. Recent studies have used microarrays and sequencing to comprehensively identify all somatic genetic alterations in acute lymphoblastic leukemia (ALL). These studies have identified cryptic or submicroscopic genetic alterations that define new ALL subtypes, cooperate with known chromosomal rearrangements, and influence prognosis. This article reviews these advances, discusses results from ongoing second-generation sequencing studies of ALL, and highlights challenges and opportunities for future genetic profiling approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“BCP-ALL, which is characterized by a block in lymphoid differentiation leading to the accumulation of immature progenitor cells.37”
From PELI2 regulates early B-cell progenitor differentiation and related leukemia via the IL-7R expression (2023) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243 · cited 1×
“org Volume 122 Number 10 October 2012 3409 such as imatinib mesylate (Gleevec) have transformed the treatment and outcome of patients with BCR-ABL1–positive leukemia (40, 41).”
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713 · cited 1×
“org Volume 122 Number 10 October 2012 3409 such as imatinib mesylate (Gleevec) have transformed the treatment and outcome of patients with BCR-ABL1–positive leukemia (40, 41).”
Yeoh, E.-J., Ross, M. E., Shurtleff, S. A., Williams, W. K., Patel, D., Mahfouz, R., Behm, F. G., Raimondi, S. C., Relling, M. V., Patel, A., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00032-6 · Cited by 1,917 · cited 1×
“These approaches, coupled with candidate gene sequencing and integrated gene expression profiling (92), have identified a number of critical new targets of mutation in B-ALL that often involve genes that regulate lymphoid development, cell cycle, tumor suppression, and a variety of other key…”
Okuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., & Downing, J. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80986-1 · Cited by 1,856
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia
Mullighan, C. G., Goorha, S., Radtke, I., Miller, C. B., Coustan-Smith, E., Dalton, J. D., Girtman, K., Mathew, S., Ma, J., Pounds, S. B., et al. (2007) · Nature · doi:10.1038/nature05690 · Cited by 1,801 · cited 6×
“The nature and frequency of these CNAs are significantly associated with ALL subtype, with few lesions in MLL-rearranged ALL (17, 55) but 6–8 lesions per case in BCR-ABL1 and ETV6-RUNX1 ALL (33, 34).”
InfluentialSelf-citationCBP/p300 in cell growth, transformation, and development
Goodman, R. H., & Smolik, S. (2000) · Genes & Development · doi:10.1101/gad.14.13.1553 · Cited by 1,778
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
Armstrong, S. A., Staunton, J. E., Silverman, L. B., Pieters, R., den Boer, M. L., Minden, M. D., Sallan, S. E., Lander, E. S., Golub, T. R., & Korsmeyer, S. J. (2002) · Nature Genetics · doi:10.1038/ng765 · Cited by 1,723
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S. L., Payne-Turner, D., Easton, J., Chen, X., Wang, J., Rusch, M., et al. (2012) · Nature · doi:10.1038/nature10725 · Cited by 1,596
Self-citationPui, C.-H., Robison, L. L., & Look, A. T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60457-2 · Cited by 1,564
Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia
Mullighan, C. G., Su, X., Zhang, J., Radtke, I., Phillips, L. A. A., Miller, C. B., Ma, J., Liu, W., Cheng, C., Schulman, B. A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808253 · Cited by 1,422 · cited 2×
“Despite their high frequency of occurrence, PAX5 alterations are not associated with outcome in ALL (81, 95).”
Self-citation
Research works printed but not linked: 2
- Andersson AK, et al. Whole genome sequence anal- ysis of 22 MLL rearranged infant acute lympho- blastic leukemias reveals remarkably few somatic mutations: a report from the St. Jude Children's Research Hospital -Washington University Pedi- atric Cancer Genome Project. ASH Annual Meeting Abstracts. 2011;118:69.
- Mullighan, 2007, 110, 691
Cited by
Inaba, H., Greaves, M., & Mullighan, C. G. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62187-4 · Cited by 1,074
Self-citationGokbuget, N., Dombret, H., Ribera, J.-M., Fielding, A. K., Advani, A., Bassan, R., Chia, V., Doubek, M., Giebel, S., Hoelzer, D., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.144311 · Cited by 227
“50 In 3 salvage Without prior HSCT 12/108 11 (6, 19) 108 2.”
Oshima, K., Khiabanian, H., da Silva-Almeida, A. C., Tzoneva, G., Abate, F., Ambesi-Impiombato, A., Sanchez-Martin, M., Carpenter, Z., Penson, A., Perez-Garcia, A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608420113 · Cited by 194
“Recurrently somatically mutated genes in our series included known oncogenes and tumor suppressors mutated in B-cell precursor ALL [KRAS, NRAS, Fms related tyrosine kinase 3 (FLT3), Janus kinase 2 (JAK2), Janus kinase 3 (JAK3), and CREBBP] (20) and T-cell ALL [Notch1 (NOTCH1), FBXW7, PHF6, DNM2, WT1, JAK1, JAK3, BCL11…”
BackgroundGenomics of racial and ethnic disparities in childhood acute lymphoblastic leukemia
Lim, J. Y., Bhatia, S., Robison, L. L., & Yang, J. J. (2014) · Cancer · doi:10.1002/cncr.28531 · Cited by 180
“Recent high-throughput genomic profiling of ALL (eg, genomewide gene expression, DNA copy number, and single nucleotide polymorphism [SNP] genotype) has dramatically improved our understanding of the genetic landscape of this disease and has also led to the discovery of novel molecular markers for treatment individual…”
BackgroundPalanichamy, J. K., Tran, T. M., Howard, J. M., Contreras, J. R., Fernando, T. R., Sterne-Weiler, T., Katzman, S., Toloue, M., Yan, W., Basso, G., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci80046 · Cited by 168
“org Volume 126 Number 4 April 2016 Introduction Oncogenesis in early B cell progenitors results in B cell acute lymphoblastic leukemia (B-ALL), the most prevalent hematological neoplasm in children and young adults (1).”
BackgroundMukherjee, S., Patra, R., Behzadi, P., Masotti, A., Paolini, A., & Sarshar, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1244345 · Cited by 166
The lncRNA CASC15 regulates SOX4 expression in RUNX1-rearranged acute leukemia
Fernando, T. R., Contreras, J. R., Zampini, M., Rodriguez-Malave, N. I., Alberti, M. O., Anguiano, J., Tran, T. M., Palanichamy, J. K., Gajeton, J., Ung, N. M., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0692-x · Cited by 146
“RUNX1 mutations and translocations are amongst the most commonly seen mutations in hematologic malignancies [44 – 46].”
Childhood B-acute lymphoblastic leukemia: a genetic update
Woo, J. S., Alberti, M. O., & Tirado, C. A. (2014) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-3-16 · Cited by 148
“Mutations occur in about 10% of high-risk childhood B-ALL cases [73].”
BackgroundLenk, L., Alsadeq, A., & Schewe, D. M. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09848-z · Cited by 137
Predicting relapse risk in childhood acute lymphoblastic leukaemia
Teachey, D. T., & Hunger, S. P. (2013) · British Journal of Haematology · doi:10.1111/bjh.12442 · Cited by 118
“(Hunger et al, 2011; Moorman, 2012; Mullighan, 2012).”
BackgroundInfluentialGökbuget, N., Boissel, N., Chiaretti, S., Dombret, H., Doubek, M., Fielding, A. K., Foà, R., Giebel, S., Hoelzer, D. F., Hunault, M., et al. (2024) · Blood · doi:10.1182/blood.2023020794 · Cited by 137
“RAS and JAK/STAT mutations are detected in both B-and T-LIN 22 .”
Five percent of healthy newborns have an ETV6-RUNX1 fusion as revealed by DNA-based GIPFEL screening
Schäfer, D., Olsen, M., Laehnemann, D., Stanulla, M., Slany, R. K., Schmiegelow, K., Borkhardt, A., & Fischer, U. (2018) · Blood · doi:10.1182/blood-2017-09-808402 · Cited by 115
“3 Pediatric acute lymphoblastic leukemia (ALL) is characterized by recurrent preleukemic chromosomal translocations that emerge frequently in utero.(1) The most common translocation t(12;21) occurs in 25% of B-cell precursor ALL and results in”
BackgroundResultLncRNA Expression Discriminates Karyotype and Predicts Survival in B-Lymphoblastic Leukemia
Fernando, T. R., Rodriguez-Malave, N. I., Waters, E. V., Yan, W., Casero, D., Basso, G., Pigazzi, M., & Rao, D. S. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0006-t · Cited by 115
“It is now well recognized that commonly observed recurrent chromosomal abnormalities have distinct pathogenetic and prognostic implications (21, 22).”
BackgroundMethodInfluentialTasian, S. K., & Hunger, S. P. (2016) · British Journal of Haematology · doi:10.1111/bjh.14474 · Cited by 101
“Although rare (<0 5% of children with B-ALL), the TCF3-HLF fusion resulting from t(17;19)(q22;p13 3) is associated with extremely poor outcomes (Mullighan, 2012).”
BackgroundMutational Landscape of Pediatric Acute Lymphoblastic Leukemia
Ding, L., Sun, Q., Tan, K. T., Chien, W., Mayakonda, A., Yeoh, A. E. J., Kawamata, N., Nagata, Y., Xiao, J., Loh, X.-Y., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1303 · Cited by 90
“Cytogenetic alterations are frequent, and several molecular markers have been identified to predict prognosis (1): ALL patients with high hyperdiploid chromosomes are usually associated with a better survival, while those with low hypodiploid chromosomes usually have a worse prognosis (1).”
BackgroundSuperenhancer reprogramming drives a B-cell–epithelial transition and high-risk leukemia
Hu, Y., Zhang, Z., Kashiwagi, M., Yoshida, T., Joshi, I., Jena, N., Somasundaram, R., Emmanuel, A. O., Sigvardsson, M., Fitamant, J., et al. (2016) · Genes & Development · doi:10.1101/gad.283762.116 · Cited by 88
Childhood acute lymphoblastic leukemia: Integrating genomics into therapy
Tasian, S. K., Loh, M. L., & Hunger, S. P. (2015) · Cancer · doi:10.1002/cncr.29573 · Cited by 85
“5% of patients with B-ALL and, despite its rarity, has been associated with extremely poor outcomes.(35,36) KMT2A is a promiscuous oncogene with rearrangements involving >75 fusion partners, and the incidence of KMT2A rearrangements in childhood B-ALL differs markedly by age.”
BackgroundCaron, M., St-Onge, P., Sontag, T., Wang, Y. C., Richer, C., Ragoussis, J., Sinnett, D., & Bourque, G. (2020) · Scientific Reports · doi:10.1038/s41598-020-64929-x · Cited by 88
RUNX1‐dependent mechanisms in biological control and dysregulation in cancer
Hong, D., Fritz, A. J., Gordon, J. A. R., Tye, C. E., Boyd, J. R., Tracy, K. M., Frietze, S. E., Carr, F. E., Nickerson, J. A., van Wijnen, A. J., et al. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27841 · Cited by 83
“RUNX1 is also one of the most frequently mutated genes in MDS and ALL, about 10% and 25% respectively (Bejar et al., 2011; Grossmann et al., 2011; Haferlach et al., 2014; Mullighan, 2012; Papaemmanuil et al., 2013; Speck & Gilliland, 2002).”
BackgroundLNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors
Cheng, Y., Chikwava, K. R., Wu, C., Zhang, H., Bhagat, A., Pei, D., Choi, J. K., & Tong, W. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81468 · Cited by 76
Nanomedicine approaches in acute lymphoblastic leukemia
Tatar, A.-S., Nagy-Simon, T., Tomuleasa, C., Boca, S., & Aştilean, S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.07.035 · Cited by 75
Genome sequencing of lymphoid malignancies
Mullighan, C. G. (2013) · Blood · doi:10.1182/blood-2013-08-460311 · Cited by 67
“Although these alterations are important initiating lesions in leukemogenesis, they are usually insufficient to induce leukemia in experimental models, and extensive microarray and candidate gene sequencing studies have identified a number of additional recurring genetic alterations in leukemogenesis, treatment failur…”
BackgroundSelf-citationOshima, K., Zhao, J., Pérez‐Durán, P., Brown, J. A., Patiño-Galindo, J. Á., Chu, T. H., Quinn, S. A., Gunning, T. S., Belver, L., Ambesi‐Impiombato, A., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00124-1 · Cited by 70
Risk Factors for Childhood Leukemia: Radiation and Beyond
Schmidt, J.-A., Hornhardt, S., Erdmann, F., Sánchez-García, I., Fischer, U., Schüz, J., & Ziegelberger, G. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.805757 · Cited by 69
“Preleukemic Clones pB-ALL shows several biologically distinct subtypes defined by chromosomal alterations of which the most frequent are aneuploidy and chromosomal translocations (16).”
BackgroundSynergism of FAK and tyrosine kinase inhibition in Ph+ B-ALL
Churchman, M. L., Evans, K., Richmond, J., Robbins, A. K., Jones, L., Shapiro, I. M., Pachter, J. A., Weaver, D. T., Houghton, P. J., Smith, M. A., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.86082 · Cited by 58
“Genetic alterations resulting in loss of function or dominant-negative inhibition of B lineage transcription factors are a hallmark of B progenitor ALL (13), with significant differences observed in the nature of alteration between B-ALL subtypes.”
BackgroundSelf-citationHungate, E. A., Vora, S., Gamazon, E. R., Moriyama, T., Best, T., Hulur, I., Lee, Y., Evans, T., Ellinghaus, E., Stanulla, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms10635 · Cited by 59
“Using the EA and AA LCL data sets described above29,30, we also investigated genotypedependent coexpression between CDKN2B and every TF that either: (1) possessed a binding motif (defined by JASPER67 or TRANSFAC28) containing an SNP in the rs77728904-tagged locus or (2) was confirmed by ChIP-seq to bind to a sequence…”
Busche, S., Ge, B., Vidal, R. O., Spinella, J.-F., Saillour, V., Richer, C., Healy, J., Chen, S., Droit, A., Sinnett, D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4367 · Cited by 61
de Haas, V., Ismaila, N., Advani, A. S., Arber, D. A., Dabney, R. S., Patel‐Donnelly, D., Kitlas, E., Pieters, R., Pui, C., Sweet, K. L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.01468 · Cited by 61
“karyotyping in ALL cases, FISH or PCR for BCR-ABL1 should be performed in concordance with NGS studies of ALL that may be adopted to identify cryptic or submicroscopic genetic alterations that define all B-ALL subtypes including BCR-ABL1-like variant.(30) In addition, testing for KMT2A (MLL) translocations is recommen…”
BackgroundMethodWhy Do Children with Acute Lymphoblastic Leukemia Fare Better Than Adults?
Neaga, A., Jimbu, L., Mesaros, O., Bota, M., Lazar, D. R., Cainap, S. S., Blag, C. L., & Zdrenghea, M. (2021) · Cancers · doi:10.3390/cancers13153886 · Cited by 52
Bashford-Rogers, R. J. M., Nicolaou, K. A., Bartram, J. L., Goulden, N., Loizou, L., Koumas, L., Chi, J., Hubank, M. J. F., Kellam, P., Costeas, P., et al. (2016) · Leukemia · doi:10.1038/leu.2016.142 · Cited by 52
Perim, A. D. L., Amarante, M. K., Guembarovski, R. L., de Oliveira, C. E. C., & Watanabe, M. A. E. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1830-x · Cited by 50
Nonhistone targets of KAT2A and KAT2B implicated in cancer biology
Bondy‐Chorney, E., Denoncourt, A. M., Sai, Y., & Downey, M. (2018) · Biochemistry and Cell Biology · doi:10.1139/bcb-2017-0297 · Cited by 51
STAT3 mediates oncogenic addiction to TEL-AML1 in t(12;21) acute lymphoblastic leukemia
Mangolini, M., de Boer, J., Walf-Vorderwülbecke, V., Pieters, R., den Boer, M. L., & Williams, O. (2013) · Blood · doi:10.1182/blood-2012-11-465252 · Cited by 53
“However, TEL-AML1 has been shown to be capable of generating pre-leukemic clones(11) and of being predisposed to hematologic disease,(10,12,13) but on its own it does not appear to be sufficient to induce overt leukemia.(14) This is consistent with clinical data in which the translocation is already detectable years b…”
ResultRUNX transcription factors at the interface of stem cells and cancer
Deltcheva, E. M., & Nimmo, R. A. (2017) · Biochemical Journal · doi:10.1042/bcj20160632 · Cited by 53
Kraus, H., Kaiser, S., Aumann, K., Bönelt, P., Salzer, U., Vestweber, D., Erlacher, M., Kunze, M., Burger, M., Pieper, K., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301815 · Cited by 48
“c-ABL, and IKAROS are frequently found in pre-B acute lymphoblastic leukemia (51), thus emphasizing the prominent role of the pre-BCR in regulating growth and differentiation of human precursor B cells.”
BackgroundBerry, N., Scott, R. J., Rowlings, P., & Enjeti, A. K. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.07.016 · Cited by 46
Fadoo, Z., Nisar, M. I., Yousuf, F. S., Lakhani, L. S., Ashraf, S., Imam, U., Zaheer, J., Naqvi, A., & Belgaumi, A. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25583 · Cited by 44
“8%) when compared to the 20% reported in the literature.[30] Hyperdiploidy has been associated with an excellent prognosis.”
BackgroundResultInfluentialZhang, X., Rastogi, P., Shah, B. D., & Zhang, L. (2017) · Oncotarget · doi:10.18632/oncotarget.19271 · Cited by 48
“Approximately 75% of B-ALL cases have recurrent chromosomal changes detectable by conventional cytogenetic analysis [9], many of which have impacts on prognosis and are used for risk stratification on some treatment protocols [10] (Table 1, Figure 1).”
BackgroundTharkar-Promod, S., Johnson, D. P., Bennett, S. E., Dennis, E. M., Banowsky, B. G., Jones, S. S., Shearstone, J. R., Quayle, S. N., Min, C., Jarpe, M. B., et al. (2017) · Leukemia · doi:10.1038/leu.2017.174 · Cited by 43
“The Ph chromosome results in BCR-ABL1 fusion gene, giving rise to the BCR-ABL1 oncoprotein, which drives B-cell precursor acute lymphoblastic leukemia (ALL) and chronic myelogenous leukemia (CML) 1,2 .”
Hein, D., Dreisig, K., Metzler, M., Izraeli, S., Schmiegelow, K., Borkhardt, A., & Fischer, U. (2019) · Blood · doi:10.1182/blood.2019002215 · Cited by 42
FOXO in B-cell lymphopoiesis and B cell neoplasia
Ushmorov, A., & Wirth, T. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.07.008 · Cited by 42
Yoshida, T., Hu, Y., Zhang, Z., Emmanuel, A. O., Galani, K., Muhire, B. M., Snippert, H. J. G., Williams, C. J., Tolstorukov, M. Y., Gounari, F., et al. (2019) · Genes & Development · doi:10.1101/gad.321901.118 · Cited by 40
“Human leukemias that derive from early steps in B-cell differentiation frequently harbor inactivating mutations in these transcription regulators, highlighting their importance in promoting progression through differentiation intermediates that are potentially leukemogenic (Mullighan 2012).”
Szczepanek, J. (2020) · World Journal of Clinical Oncology · doi:10.5306/wjco.v11.i6.348 · Cited by 40
Janczar, S., Janczar, K., Pastorczak, A. K., Harb, H., Paige, A. J. W., Zalewska‐Szewczyk, B., Danilewicz, M., & Mlynarski, W. M. (2017) · Cancers · doi:10.3390/cancers9010002 · Cited by 37
“In BCP-ALL t(11q23) MLL1 gene translocations (best described MLL1-AF4 ) are associated with high risk disease and are an established cytogenetic risk factor for a few decades [81,82].”
BackgroundRazali, R. H., Noorizhab, M. N. F., Jamari, M. H., James, R. J., Teh, K. H., Ibrahim, H. M., Teh, L. K., & Salleh, M. Z. (2019) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2019.1705949 · Cited by 36
“Therefore, this study aims to investigate the association of the variation of four genes ARID5B, ABCC2, SLCO1B1 and MTHFR with serum level and toxicity of MTX among the Malaysian children with ALL.”
BackgroundInfluentialBALR-6 regulates cell growth and cell survival in B-lymphoblastic leukemia
Rodriguez-Malave, N. I., Fernando, T. R., Patel, P. C., Contreras, J. R., Palanichamy, J. K., Tran, T. M., Anguiano, J., Davoren, M. J., Alberti, M. O., Pioli, K. T., et al. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0485-z · Cited by 38
Navarrete-Meneses, M. D. P., Salas‐Labadía, C., Sanabrais‐Jiménez, M. A., Santana-Hernández, J., Serrano-Cuevas, A., Juárez-Velázquez, R., Olaya‐Vargas, A., & Pérez‐Vera, P. (2017) · Toxicology in Vitro · doi:10.1016/j.tiv.2017.06.013 · Cited by 36
Genetic and Epigenetic Targeting Therapy for Pediatric Acute Lymphoblastic Leukemia
Xu, H., Yu, H., Jin, R., Wu, X., & Chen, H. (2021) · Cells · doi:10.3390/cells10123349 · Cited by 37
“In addition, TCF3-HLF fusion is associated with extremely poor outcomes [37].”
BackgroundBaughn, L. B., Biegel, J. A., South, S. T., Smolarek, T. A., Volkert, S., Carroll, A. J., Heerema, N. A., Rabin, K. R., Zweidler‐McKay, P. A., Loh, M. L., et al. (2014) · Cancer Genetics · doi:10.1016/j.cancergen.2014.11.003 · Cited by 32
“2),þmar[2]/46,XX[12] 91 11 47,XX,þ21[3]/46,XX[27] 87 12”
InfluentialLong non-coding RNAs in B-cell malignancies: a comprehensive overview
Nobili, L., Ronchetti, D., Taìana, E., & Neri, A. (2017) · Oncotarget · doi:10.18632/oncotarget.17303 · Cited by 32
“In B-ALL, mutations and translocations occurring in precursor B-cells result in dysregulated gene expression [33, 34].”
BackgroundLajoie, M., Drouin, S., Caron, M., St-Onge, P., Ouimet, M., Gioia, R., Lafond, M.-H., Vidal, R. O., Richer, C., Oualkacha, K., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174124 · Cited by 35
Leung, K. T., Zhang, C., Chan, K. Y. Y., Li, K., Cheung, J. T. K., Ng, M. H. L., Zhang, X., Sit, T., Lee, W., Kang, W., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0593-7 · Cited by 30
“The reason behind the exclusive expression of CD9 in hyperdiploid and TCF3-PBX1 cases remains unclear as these subtypes are generally associated with a favorable prognosis [4].”
BackgroundSomatic drivers of B-ALL in a model of ETV6-RUNX1; Pax5 +/− leukemia
van der Weyden, L., Giotopoulos, G., Wong, K., Rust, A. G., Robles‐Espinoza, C. D., Osaki, H., Huntly, B. J. P., & Adams, D. J. (2015) · BMC Cancer · doi:10.1186/s12885-015-1586-1 · Cited by 30
“B-cell precursor acute lymphoblastic leukemia (B-ALL) is the most common childhood tumor [1].”
BackgroundGhazavi, F., Lammens, T., Roy, N. V., Poppe, B. G., Speleman, F., Benoît, Y., Vlierberghe, P. V., & Moerloose, B. D. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.015 · Cited by 30
Messina, M., Chiaretti, S., Wang, J., Fedullo, A. L., Peragine, N., Gianfelici, V., Piciocchi, A., Brugnoletti, F., Giacomo, F. D., Pauselli, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7356 · Cited by 31
“Given the low number of recurrently mutated genes detected in the discovery panel, WES was broadened to 68 additional B-NEG cases (screening panel 1) and the bioinformatic analysis focused on the genes mutated in the discovery panel and/or reported as affected by mutations or CNAs in published ALL series [25-29].”
BackgroundFrom Cancer Genomics to Precision Oncology—Tissue’s Still an Issue
Cohen, R. L., & Settleman, J. (2014) · Cell · doi:10.1016/j.cell.2014.05.027 · Cited by 32
Satake, N., Duong, C., Chen, C. Y.-H., Barisone, G. A., Díaz, E., Tuscano, J. M., Rocke, D. M., Nolta, J. A., & Nitin, N. (2014) · British Journal of Haematology · doi:10.1111/bjh.13066 · Cited by 30
“Leukaemia is the most common malignancy in children, with precursor B-cell (preB) acute lymphoblastic leukaemia (ALL) being the most common type (Mullighan, 2012; Wiemels, 2012).”
BackgroundEpigenetic alterations in acute lymphoblastic leukemia
Navarrete-Meneses, M. D. P., & Pérez‐Vera, P. (2017) · Boletín Médico Del Hospital Infantil de México (English Edition) · doi:10.1016/j.bmhime.2018.01.004 · Cited by 34
“15,16 The t(1;19)(q23;p13) translocation leads to the fusion of TCF3-PBX1 genes and is present in 5-6% of the cases of pediatric ALL.”
BackgroundWatanabe, A., Miyake, K., Nordlund, J., Syvänen, A.-C., van der Weyden, L., Honda, H., Yamasaki, N., Nagamachi, A., Inaba, T., Ikawa, T., et al. (2020) · Blood · doi:10.1182/blood.2019004090 · Cited by 27
Diedrich, J. D., Dong, Q., Ferguson, D. C. J., Bergeron, B. P., Autry, R. J., Qian, M., Yang, W., Smith, C. J., Papizan, J. B., Connelly, J. P., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01209-1 · Cited by 28
Cell of origin dictates aggression and stem cell number in acute lymphoblastic leukemia
Garcia, E. G., Iyer, S., Garcia, S. P., Loontiens, S., Sadreyev, R. I., Speleman, F., & Langenau, D. M. (2018) · Leukemia · doi:10.1038/s41375-018-0130-0 · Cited by 26
“By contrast, B-ALLs are more frequently driven by chromosomal rearrangements that create fusion oncogenes and have recurrent chromosomal aberrations [5].”
Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (Review)
Evangelisti, C., Evangelisti, C., Chiarini, F., Lonetti, A., Buontempo, F., Bressanin, D., Cappellini, A., Orsini, E., McCubrey, J. A., & Martelli, A. M. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2525 · Cited by 28
Messina, M., Chiaretti, S., Fedullo, A. L., Piciocchi, A., Puzzolo, M. C., Lauretti, A., Gianfelici, V., Apicella, V., Fazi, P., Kronnie, G. T., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14721 · Cited by 25
Transcriptional circuits in B cell transformation
Hu, Y., Yoshida, T., & Georgopoulos, K. (2017) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000352 · Cited by 26
Resistance of t(17;19)‐acute lymphoblastic leukemia cell lines to multiagents in induction therapy
Watanabe, A., Inukai, T., Kagami, K., Abe, M., Takagi, M., Fukushima, T., Fukushima, H., Nanmoku, T., Terui, K., Ito, T., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2356 · Cited by 26
Vellichirammal, N. N., Chaturvedi, N. K., Joshi, S. S., Coulter, D. W., & Guda, C. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.015 · Cited by 26
Glycoproteome remodeling in MLL-rearranged B-cell precursor acute lymphoblastic leukemia
Oliveira, T., Zhang, M., Joo, E. J., Abdel‐Azim, H., Chen, C.-W. D., Yang, L., Chou, C.-H., Qin, X., Chen, J., Alagesan, K., et al. (2021) · Theranostics · doi:10.7150/thno.65398 · Cited by 25
Vitanza, N. A., Zaky, W. T., Blum, R., Meyer, J. A., Wang, J., Bhatla, T., Morrison, D. J., Raetz, E. A., & Carroll, W. L. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25119 · Cited by 28
Jain, P. L., Korula, A., Deshpande, P. A., Nisham, P. N., Alex, A. A., Abraham, A., Srivastava, A., Arthur, N. B. J., Lakshmi, K. M., Balasubramanian, P., et al. (2018) · Journal of Global Oncology · doi:10.1200/jgo.17.00014 · Cited by 24
“(%) P SR (n = 344) HR (n = 163) Age, years 25 (15-67)* 32 (15-67)* < .”
BackgroundMontecino‐Rodriguez, E., Li, K., Fice, M. P., & Dorshkind, K. A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1303170 · Cited by 25
“We considered the possibility that TSLP responsiveness was responsible for the aggressive nature of B-1 progenitor ALL, because B-1, but not B-2, progenitors are TSLP responsive (6, 9) and CRLF2 expression has been associated with poor ALL outcome (17, 30, 31).”
BackgroundZebrafish Models of Human Leukemia: Technological Advances and Mechanistic Insights
Harrison, N. R., Laroche, F., Gutiérrez, A., & Feng, H. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-30654-4_15 · Cited by 24
“Chromosomal rearrangements affecting genes related to hematopoiesis, tumor control, and tyrosine kinase activity are common and in combination with further genetic aberrations such as tumor suppressor inactivation and aberrant oncogene activation, lead to the leukemic phenotype [78].”
BackgroundAkkari, Y. M. N., Bruyèrè, H., Hagelstrom, R. T., Kanagal‐Shamanna, R., Liu, J., Luo, M., Mikhail, F. M., Pitel, B. A., Raca, G., Shago, M., et al. (2020) · Cancer Genetics · doi:10.1016/j.cancergen.2020.03.001 · Cited by 25
Epigenetic balance ensures mechanistic control of MLL amplification and rearrangement
Gray, Z. H., Chakraborty, D., Duttweiler, R. R., Alekbaeva, G. D., Murphy, S. E., Chetal, K., Ji, F., Ferman, B. I., Honer, M. A., Wang, Z., et al. (2023) · Cell · doi:10.1016/j.cell.2023.09.009 · Cited by 24
Laurent, A. P., Siret, A., Ignacimouttou, C., Panchal, K., Diop, M. K., Jenni, S., Tsai, Y.-C., Roos‐Weil, D., Aid, Z., Prade, N., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3519 · Cited by 25
Alteraciones epigenéticas en leucemia linfoblástica aguda
Navarrete-Meneses, M. D. P., & Pérez‐Vera, P. (2017) · Boletín Médico del Hospital Infantil de México · doi:10.1016/j.bmhimx.2017.02.005 · Cited by 36
Epigenetic Mechanisms in Leukemias and Lymphomas
Duy, C., Béguelin, W., & Melnick, A. M. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a034959 · Cited by 24
Acute Lymphoblastic Leukemia in Adolescents and Young Adults
Burke, P. W., & Douer, D. (2014) · Acta Haematologica · doi:10.1159/000360204 · Cited by 22
Jaiswal, A. K., Truong, H., Tran, T. M., Lin, T. L., Casero, D., Alberti, M. O., & Rao, D. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-92448-w · Cited by 25
Wray, J. P., Deltcheva, E. M., Böiers, C., Richardson, S. E., Chhetri, J. B., Brown, J., Gagrica, S., Guo, Y., Illendula, A., Martens, J. H. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34653-3 · Cited by 28
“582483 cells) or a non-targeting control (t(12;21): 12777 cells, t(5;21): 1084188 cells).”
BackgroundMethodInfluentialBarnett, K. R., Mobley, R. J., Diedrich, J. D., Bergeron, B. P., Bhattarai, K. R., Monovich, A. C., Narina, S., Yang, W., Crews, K. R., Manring, C. S., et al. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100442 · Cited by 24
“2 Numerous studies have identified extensive heterogeneity in transcriptomes 3,4 and DNA methylomes 5,6 among B-ALL subtypes in large patient cohorts, but there is limited understanding of chromatin landscapes.”
BackgroundSelf-citationRowsey, R. A., Smoley, S. A., Williamson, C. M., Vasmatzis, G., Smadbeck, J. B., Ning, Y., Greipp, P. T., Hoppman, N. L., Baughn, L. B., Ketterling, R. P., et al. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0239-z · Cited by 22
Dargenio, M., Bonifacio, M., Chiaretti, S., Vitale, A., Fracchiolla, N. S., Papayannidis, C., Giglio, F., Salutari, P., Audisio, E., Scappini, B., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18537 · Cited by 21
In Utero Development and Immunosurveillance of B Cell Acute Lymphoblastic Leukemia
Rüchel, N., Jepsen, V. H., Hein, D., Fischer, U., Borkhardt, A., & Gössling, K. L. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-00963-3 · Cited by 21
ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia
Germanò, G., Morello, G., Aveic, S., Pinazza, M., Minuzzo, S. A., Frasson, C., Persano, L., Bonvini, P., Viola, G., Bresolin, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15387 · Cited by 22
“Furthermore, GSEA revealed a negative enrichment with genes that are upregulated in MLL-rearranged pediatric AML compared with non-MLL-rearranged AML [29]”
BackgroundDefining the significance of IGF2BP1 overexpression in t(12;21)(p13;q22)-positive leukemia REH cells
Stoškus, M., Eidukaitė, A., & Griškevičius, L. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.05.009 · Cited by 21
Emerging biological therapies to treat acute lymphoblastic leukemia
Huguet, F., & Tavitian, S. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1257606 · Cited by 22
Clay‐Gilmour, A., Hahn, T., Preus, L. M., Onel, K., Skol, A. D., Hungate, E. A., Zhu, Q., Haiman, C. A., Stram, D. O., Pooler, L., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017006023 · Cited by 23
“IKZF1 is a transcription factor that is needed for development of hematopoietic stem cells to lymphoid precursors.(71,72) It is frequently targeted by copynumber alterations in ALL blast cells (particularly in high-risk ALL); deletions and mutations result in loss of function or dominantnegative isoforms(73) and are a…”
BackgroundPediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolution
Richter‐Pechańska, P., Kunz, J. B., Rausch, T., Erarslan-Uysal, B., Bornhauser, B. C., Frismantas, V., Assenov, Y., Zimmermann, M., Happich, M., Doeberitz, C. V. K., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01587-0 · Cited by 21
“While several genetic parameters determining risk are known for precursor B-ALLs [41], risk stratification of T-ALL is still largely based on the kinetics of treatment response [42].”
BackgroundUnpeaceful roles of mutant PAX proteins in cancer
Wachtel, M., & Schäfer, B. W. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.09.011 · Cited by 23
Andersson, A., Moorman, A. V., Harrison, C. J., & Mullighan, C. G. (2016) · Wiley eBooks · doi:10.1002/9781118527948.ch5 · Cited by 19
Self-citationCaron, M., St-Onge, P., Drouin, S., Richer, C., Sontag, T., Busche, S., Bourque, G., Pastinen, T., & Sinnett, D. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207250 · Cited by 21
Midkine as a regulator of B cell survival in health and disease
Cohen, S., & Shachar, I. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12419 · Cited by 19
“Despite impressive advances in the outcome of therapy with cure rates now exceeding 80%, ALL remains a leading cause of cancer-related death in children and young adults (Pui et al., 2009a,b; Mullighan, 2012).”
BackgroundLong noncoding RNAs in hematopoietic malignancies
Rodriguez-Malave, N. I., & Rao, D. S. (2015) · Briefings in Functional Genomics · doi:10.1093/bfgp/elv047 · Cited by 19
“Years of research have identified recurrent cytogenetic abnormalities in B-ALL, including four common translocations, fusion of the ETS variant 6 (ETV6) and RUNX1 genes (ETV6-RUNX1), BCR-ABL, mixed lineage leukemia (MLL) rearrangements and fusion protein of E2A and PBX1 genes (E2APBX1), which account for about 30% of…”
BackgroundBahjat, M., de Wilde, G., van Dam, T. P., Maas, C., Bloedjes, T. A., Bende, R. J., van Noesel, C. J. M., Luijks, D. M., Eldering, E., Kersten, M. J., et al. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1646068 · Cited by 21
“However, in childhood leukemias, it is an uncommon event (2–5%) [2].”
BackgroundBrissot, É., Labopin, M., Russo, D., Martin, S., Schmid, C., Glaß, B., Ram, R., Özkurt, Z. N., Passweg, J. R., Veelken, J. H., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-0849-x · Cited by 19
Epigenetic Regulation of Cell Signaling Pathways in Acute Lymphoblastic Leukemia
José‐Eneriz, E. S., Agirre, X., Rodríguez‐Otero, P., & Prósper, F. (2013) · Epigenomics · doi:10.2217/epi.13.56 · Cited by 21
Choi, J., Polcher, A. A., & Joas, A. (2016) · EFSA Supporting Publications · doi:10.2903/sp.efsa.2016.en-955 · Cited by 18
miRNA Deregulation in Childhood Acute Lymphoblastic Leukemia: A Systematic Review
Gutiérrez-Camino, Á., García‐Obregón, S., López-López, E., Astigarraga, I., & García‐Orad, Á. (2019) · Epigenomics · doi:10.2217/epi-2019-0154 · Cited by 19
Effect of GSTM1 null genotype on risk of childhood acute leukemia: a meta-analysis
Ma, Y., Yun, S., Wang, L., & Huirong, L. (2013) · Tumor Biology · doi:10.1007/s13277-013-1055-x · Cited by 17
“Currently, the candidates for childhood acute leukemia susceptibility genes have been mainly categorized into those coding for carcinogen metabolism enzymes, folate metabolism enzymes, and DNA repair proteins [3, 4].”
BackgroundLymphoid malignancies: many tumor types, many altered genes, many therapeutic challenges
Dalla‐Favera, R. (2012) · Journal of Clinical Investigation · doi:10.1172/jci66307 · Cited by 17
Metadata
- Authors
- Mullighan, C. G.
- Affiliations
- St. Jude Children's Research Hospital (US)
- Corresponding author
- Mullighan, Charles G.
- Venue
- Journal of Clinical Investigation
- Published
- 2012-10-01
- Volume
- 122
- Issue
- 10
- Pages
- 3407-3415
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3461902
- OpenAlex
- W2146473098
- Cited by
- 247
- References
- 127
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 12 · 2023: 10 · 2022: 15 · 2021: 17 · 2020: 22 · 2019: 21 · 2018: 15 · 2017: 30 · 2016: 32 · 2015: 16 · 2014: 20 · 2013: 17 · 2012: 1
- FWCI
- 2.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Funders
- American Society of Hematology
- St. Jude Children's Research Hospital
- American Lebanese Syrian Associated Charities (38105)
- Children’s Oncology Group
- Stand Up To Cancer
- National Cancer Institute
- Topics
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomic variations and chromosomal abnormalities
- Keywords
- B-cell precursor acute lymphoblastic leukemia, somatic alterations, chromosomal rearrangements, aneuploidy, prognosis, leukemogenesis, genetic profiling, childhood cancer
- MeSH terms
- Adult, Animals, B-Lymphocytes, Child, Clone Cells, Hematopoietic Stem Cells, Humans, Neoplasm Proteins, Prognosis, Risk, Translocation, Genetic, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Oncogene Proteins, Fusion, Mice, Knockout, Cell Lineage, Genetic Predisposition to Disease, Gene Expression Profiling, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.